Diakonos Oncology Raises $20M in Funding

| Posted on |

Here’s a structured list based on the provided information regarding Diakonos Oncology Corp.:

Company Overview

  • Startup: Diakonos Oncology Corp.
  • Location: Houston, TX
  • Sector: Biotechnology (Immunotherapy)

Fundraise Details

  • Fundraise Type: Private placement of Simple Agreements for Future Equity (SAFE)
  • Amount Raised: $20 million
  • Closing Date: Not specified (but mentioned as of January 6, 2025)

Previous Fundraising

  • Previous Round: Seed Financing
  • Amount: $11.4 million
  • Status: Closed last year (2024)

Future Fundraising Plans

  • Next Round: Series A
  • Planned Launch: Second half of 2025

Investors

  • New Investors:

    • Baylor College of Medicine (BCM)
    • Brain Tumor Investment Fund (BTIF)
    • Buttonwood Titan QC Fund
  • Existing Shareholders:
    • Mike Wicks (CEO)

Founders and Key Executives

  • CEO: Mike Wicks
  • President and COO: Jay Hartenbach

Use of Funds

  • To accelerate Phase 2 glioblastoma trial for dubodencel (DOC1021)
  • Expand clinical portfolio to include other indications such as refractory melanoma

Technology Overview

  • Product: Dubodencel (DOC1021)
  • Description: First-in-class, double-loaded autologous dendritic cell therapy using tumor lysate and amplified tumor-derived mRNA.

This well-structured summary provides a comprehensive view of Diakonos Oncology Corp.’s recent activities, funding, and leadership.

Source link

2025-06-01 17:08:15